Skip to main content

Table 5 Ten-year risk of death in relation to Recurrence Score and tumor size and grade among ER-positive patients, stratified by treatment with tamoxifen

From: A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients

Risk classifier Cases Controls 10-Year risk
    % 95% CI
Tamoxifen treated
Recurrence Score (55 cases and 150 controls)
   Low (<18) 29% 63% 2.8 (1.7–3.9)
   Intermediate (18–30) 40% 23% 10.7 (6.3–14.9)
   High (≥31) 31% 13% 15.5 (7.6–22.8)
Tumor size (55 cases and 150 controls)
   ≤1 cm 16% 31% 3.6 (1.7–5.5)
   1.1–2 cm 44% 43% 5.8 (3.7–7.8)
   >2 cm 40% 26% 9.3 (5.5–13.1)
Tumor grade (55 cases and 150 controls)
   Well 11% 33% 2.1 (0.7–3.5)
   Moderate 51% 46% 6.9 (4.7–9.0)
   Poor 38% 21% 9.9 (6.0–13.7)
Tumor size and grade (55 cases and 150 controls)
   ≤2 cm and well or ≤1 cm and moderate 15% 43% 2.5 (1.2–3.9)
   >2 cm and well, or 1.1–2 cm and moderate, or ≤2 cm and poor 49% 39% 7.2 (4.9–9.5)
   >2 cm and moderate/poor 36% 18% 11.5 (6.6–16.2)
Recurrence Score, tumor size and grade
   Recurrence Score low <18 (16 cases and 95 controls)     
≤2 cm and well or ≤1 cm and moderate 6% 46% 0.4 (0.0–1.0)
>2 cm and well, or 1.1–2 cm and moderate, or ≤2 cm and poor 63% 39% 4.1 (2.0–6.2)
>2 cm and moderate/poor 31% 15% 6.9 (1.8–11.7)
   Recurrence Score intermediate 18–30 (22 cases and 35 controls)     
≤2 cm and well or ≤1 cm and moderate 32% 51% 6.8 (2.6–10.9)
>2 cm and well, or 1.1–2 cm and moderate, or ≤2 cm and poor 45% 29% 21.9 (5.0–35.8)
>2 cm and moderate/poor 23% 20% 13.5 (1.2–24.2)
   Recurrence Score high ≥31 (17 cases and 20 controls)     
≤2 cm and well or ≤1 cm and moderate 0% 10% 12.2 (0.0–31.0)
>2 cm and well, or 1.1–2 cm and moderate, or ≤2 cm and poor 41% 60% 10.9 (2.9–18.3)
>2 cm and moderate/poor 59% 30% 28.9 (7.4–45.3)
Tamoxifen untreated
Recurrence Score (110 cases and 251 controls)
   Low (<18) 36% 64% 6.2 (4.5–7.9)
   Intermediate (18–30) 29% 19% 17.8 (11.8–23.3)
   High (≥31) 35% 18% 19.9 (14.2–25.2)
Tumor size (110 cases and 251 controls)
   ≤1 cm 29% 39% 8.5 (6.0–10.9)
   1.1–2 cm 41% 45% 10.4 (7.8–12.9)
   >2 cm 30% 16% 16.4 (11.4–21.0)
Tumor grade (110 cases and 251 controls)
   Well 15% 33% 5.5 (3.4–7.4)
   Moderate 49% 52% 11.2 (8.6–13.8)
   Poor 35% 15% 22.5 (15.9–28.6)
Tumor size and grade (110 cases and 251 controls)
   ≤2 cm and well or ≤1 cm and moderate 27% 50% 6.2 (4.3–8.0)
   >2 cm and well, or 1.1–2 cm and moderate, or ≤2 cm and poor 45% 37% 14.2 (10.8–17.4)
   >2 cm and moderate/poor 27% 13% 19.1 (13.2–24.7)
Recurrence Score, tumor size and grade
   Recurrence Score low <18 (40 cases and 160 controls)     
≤2 cm and well or ≤1 cm and moderate 35% 63% 3.0 (1.7–4.3)
>2 cm and well, or 1.1–2 cm and moderate, or ≤2 cm and poor 48% 31% 11.0 (7.0–14.8)
>2 cm and moderate/poor 17% 6% 20.2 (6.1–32.2)
   Recurrence Score intermediate 18–30 (32 cases and 47 controls)     
≤2 cm and well or ≤1 cm and moderate 34% 38% 17.0 (8.2–24.9)
>2 cm and well, or 1.1–2 cm and moderate, or ≤2 cm and poor 38% 34% 20.9 (10.2–30.4)
>2 cm and moderate/poor 28% 28% 22.0 (9.3–32.9)
   Recurrence Score high ≥31 (38 cases and 44 controls)     
≤2 cm and well or ≤1 cm and moderate 13% 14% 25.0 (7.9–39.0)
>2 cm and well, or 1.1–2 cm and moderate, or ≤2 cm and poor 50% 59% 21.0 (13.8–27.5)
>2 cm and moderate/poor 37% 27% 25.3 (15.1–34.3)
  1. CI, confidence interval; ER, estrogen receptor.